BioSpace News Archive

Cerevel Therapeutics Holdings, Inc. announced that it has commenced a private offering of $250.0 million aggregate principal amount of convertible senior notes due 2027 to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

A new study in the August 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network suggests a new way for hematologic oncologists to protect older patients from the risks of medication interactions.

Pear Therapeutics, Inc. (Nasdaq: PEAR), today announced the publication of new results from a health economic analysis of real-world data to evaluate healthcare resource utilization, associated costs and insomnia severity for Somryst® (previously known as SHUTi in its prior incarnation), the only FDA-authorized PDT for the treatment of chronic insomnia.

Virios Therapeutics, Inc., a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced that Greg Duncan, Chairman and CEO of Virios Therapeutics will be attending and presenting at the Q3 Virtual Investor Summit.

Nephros, Inc.(Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced financial results for the second quarter ended June 30, 2022.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced earlier today at the Canaccord Genuity 42nd Annual Growth Conference in Boston that the company has proactively filed a pre-submission to the FDA for its Panorama® non-invasive prenatal test (NIPT) as part of the Q-Sub process.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced financial results for the second quarter ended June 30, 2022.

Ranfac Corporation has announced the completion of a successful validation of Steris Corporation as an additional source for Ethelyn Oxide (EO) sterilization services.

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.

Panacell Biotech Co., Ltd. said that NK cells, exosomes, and brown adipose-derived stem cells are effective to treat patients with long COVID conditions, or post COVID-19 conditions, as well as those with terminal illness.